Treatment with an Estrogen Receptor Ligand Is Neuroprotective in Experimental Autoimmune Encephalomyelitis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is an inflammatory, neurodegenerative disease for which experimental autoimmune encephalomyelitis (EAE) is a model. Treatments with estrogens have been shown to decrease the severity of EAE through anti-inflammatory mechanisms. Here we investigated whether treatment with an estrogen receptor alpha (ERalpha) ligand could recapitulate the estrogen-mediated protection in clinical EAE. We then went on to examine both anti-inflammatory and neuroprotective mechanisms. EAE was induced in wild-type, ERalpha-, or ERbeta-deficient mice, and each was treated with the highly selective ERalpha agonist, propyl pyrazole triol, to determine the effect on clinical outcomes, as well as on inflammatory and neurodegenerative changes. ERalpha ligand treatment ameliorated clinical disease in both wild-type and ERbeta knock-out mice, but not in ERalpha knock-out mice, thereby demonstrating that the ERalpha ligand maintained ERalpha selectivity in vivo during disease. ERalpha ligand treatment also induced favorable changes in autoantigen-specific cytokine production in the peripheral immune system [decreased TNFalpha, interferon-gamma, and interleukin-6, with increased interleukin-5] and decreased CNS white matter inflammation and demyelination. Interestingly, decreased neuronal staining [NeuN+ (neuronal-specific nuclear protein)/beta3-tubulin+/Nissl], accompanied by increased immunolabeling of microglial/monocyte (Mac 3+) cells surrounding these abnormal neurons, was observed in gray matter of spinal cords of EAE mice at the earliest stage of clinical disease, 1-2 d after the onset of clinical signs. Treatment with either estradiol or the ERalpha ligand significantly reduced this gray matter pathology. In conclusion, treatment with an ERalpha ligand is highly selective in vivo, mediating both anti-inflammatory and neuroprotective effects in EAE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · cited 1×
“Treatment with an ER ligand reduces microglial/monocyte activation in white and gray matter of mice with EAE Gray matter axonal pathology has been described in cortex of MS patients, which was characterized by activated microglia closely opposed to and ensheathing apical dendrites, neurites, and neuronal perikarya (Pe…”
BackgroundA Gender Gap in Autoimmunity: Task Force on Gender, Multiple Sclerosis and Autoimmunity
Whitacre, C. C., Reingold, S. C., O'Looney, P. A., Blankenhorn, E., Brinley, F., Collier, E., Duquette, P., Fox, H., Giesser, B., Gilmore, W., et al. (1999) · Science · doi:10.1126/science.283.5406.1277 · Cited by 851
Self-citationExperimental autoimmune encephalomyelitis repressed by microglial paralysis
Heppner, F. L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hövelmeyer, N., Waisman, A., Rülicke, T., Prinz, M., Priller, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1177 · Cited by 732 · cited 1×
“This hypothesis is consistent with the observation that EAE clinical signs, CNS inflammation, and demyelination were each ameliorated in CD11b–HSVTK (herpes simplex virus thymidine kinase) transgenic mice, which were treated with gancyclovir and had bone marrow reconstituted from wildtype mice (Heppner et al., 2005).”
ResultIntracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration
Bø, L., Vedeler, C. A., Nyland, H., Trapp, B. D., & Mørk, S. J. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms917oa · Cited by 478 · cited 1×
“Pathological studies in cortical gray matter of MS patients initially detected axonal transection and microglial activation, with minimal inflammatory cell infiltrates (Bo et al., 2003).”
BackgroundTreatment of multiple sclerosis with the pregnancy hormone estriol
Sicotte, N. L., Liva, S. M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T. C. J., & Voskuhl, R. R. (2002) · Annals of Neurology · doi:10.1002/ana.10301 · Cited by 435
Self-citationHarris, H. A., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2002) · Endocrinology · doi:10.1210/en.2002-220403 · Cited by 357 · cited 1×
“Estradiol and PPT were dissolved in 10% ethanol and 90% oil to give the final proper con- centration of 0.04 mg/kg/d estradiol (Jansson et al., 1994) and 10 mg/ kg/d PPT per mouse (Harris et al., 2002).”
MethodInfluentialEstriol ameliorates autoimmune demyelinating disease: Implications for multiple sclerosis
Kim, S., Liva, S. M., Dalal, M. A., Verity, M. A., & Voskuhl, R. R. (1999) · Neurology · doi:10.1212/wnl.52.6.1230 · Cited by 268
Self-citationFemale sex steroids: effects upon microglial cell activation
Drew, P. D., & Chavis, J. A. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00386-6 · Cited by 209 · cited 1×
“Previously, estrogen treatment has been shown to decrease microglial activation in vitro (Drew and Chavis, 2000; Vegeto et al., 2001), but this is the first report that estrogen treatment can decrease activation in vivo.”
BackgroundDiestel, A., Aktas, O., Hackel, D., Häke, I., Meier, S., Raine, C. S., Nitsch, R., Zipp, F., & Ullrich, O. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030975 · Cited by 155 · cited 1×
“However, downregulation of microglial activation by either an ER ligand (herein) or by antisense PARP-1 [poly (ADP-ribose)polymerase-1] (Diestel et al., 2003) each resulted in decreased neuronal abnormalities in EAE.”
Background17beta‐estradiol protects oligodendrocytes from cytotoxicity induced cell death
Takao, T., Flint, N., Lee, L., Ying, X., Merrill, J., & Chandross, K. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02370.x · Cited by 93 · cited 1×
“In addition, in vitro studies have demonstrated the ability of estrogen to modulate the astrocytic response to injury (Azcoitia et al., 1999; Garcia-Segura et al., 1999) and protect oligodendrocytes from cytotoxicity (Sur et al., 2003; Cantarella et al., 2004; Takao et al., 2004).”
Background
Cited by
Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818
Voskuhl, R. R., Peterson, R. S., Song, B., Ao, Y., Morales, L. B. J., Tiwari-Woodruff, S., & Sofroniew, M. V. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1514-09.2009 · Cited by 461
Self-citationA role for sex chromosome complement in the female bias in autoimmune disease
Smith-Bouvier, D. L., Divekar, A. A., Sasidhar, M., Du, S., Tiwari-Woodruff, S. K., King, J. K., Arnold, A. P., Singh, R. R., & Voskuhl, R. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20070850 · Cited by 397
Self-citationVegeto, E., Benedusi, V., & Maggi, A. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.04.001 · Cited by 355
Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics
Shepherd, R., Cheung, A. S., Pang, K., Saffery, R., & Novakovic, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604000 · Cited by 304
Metadata
- Authors
- Morales, L. B. J., Loo, K. K., Liu, H.-B., Peterson, C., Tiwari-Woodruff, S., & Voskuhl, R. R.
- Venue
- Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-06-21
- Volume
- 26
- Issue
- 25
- Pages
- 6823-6833
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2007645945
- Cited by
- 149
- References
- 12
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.